Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).

Sophie Juul,Lehana Thabane,Sarah Klingenberg,Johan Holgersson,Fanlong Bu,Janus Christian Jakobsen,Peter Bentzer,Caroline Kamp Jørgensen,Christian Gluud,Faiza Siddiqui,Emily Barot,Joshua Feinberg,Niklas Nielsen,Emil Eik Nielsen,Areti Angeliki Veroniki,Stefanos Bonovas

doi:10.1371/journal.pone.0248132

Abstract

Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).

Highlights

In December 2019, the emergence of a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused a rapid international outbreak of the respiratory illness COVID-19 [1]
Very low certainty evidence indicates that corticosteroids might reduce the risk of death, serious adverse events, and mechanical ventilation; that remdesivir might reduce the risk of serious adverse events; that intravenous immunoglobin might reduce the risk of death and serious adverse events; that tocilizumab might reduce the risk of serious adverse events and mechanical ventilation; and that bromhexine might reduce the risk of non-serious adverse events
We identified several trials including participants suspected of COVID-19 [114, 115]

Summary

Introduction

In December 2019, the emergence of a novel coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused a rapid international outbreak of the respiratory illness COVID-19 [1]. Since the initial outbreak in China, SARS-CoV-2 has spread globally and COVID-19 is currently labeled a public health emergency of global concern by the World Health Organization [2]. The full clinical spectrum of COVID-19 ranges from asymptomatic infection to mild, self-limiting respiratory tract illness to severe progressive pneumonia, multiorgan failure, and death [3]. Many randomized clinical trials assessing the effects of different potential treatments for COVID-19 are currently underway. Effective treatments of COVID-19 are urgently needed This is the second edition of a living systematic review of randomized clinical trials assessing the effects of all treatment interventions for participants in all age groups with COVID-19

Methods

Results

Discussion

Conclusion